Q2 2024 Earnings Forecast for Krystal Biotech, Inc. Issued By William Blair (NASDAQ:KRYS)

Krystal Biotech, Inc. (NASDAQ:KRYS) – Analysts at William Blair increased their Q2 2024 earnings per share (EPS) estimates for Krystal Biotech in a report released on Monday, May 6th. William Blair analyst T. Lugo now forecasts that the company will earn $0.49 per share for the quarter, up from their prior forecast of $0.39. William Blair has a “Outperform” rating on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $1.82 per share.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analysts’ expectations of $47.37 million. During the same quarter in the previous year, the company earned ($1.76) earnings per share. Krystal Biotech’s revenue for the quarter was up 452400.0% compared to the same quarter last year.

A number of other analysts also recently commented on KRYS. Citigroup boosted their target price on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright reiterated a “buy” rating and set a $200.00 target price on shares of Krystal Biotech in a research report on Monday. Stifel Nicolaus reiterated a “buy” rating and set a $204.00 target price (up from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. Finally, Guggenheim boosted their target price on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $171.00.

Krystal Biotech Stock Performance

KRYS opened at $157.68 on Wednesday. The business’s fifty day moving average is $168.76 and its two-hundred day moving average is $134.27. The company has a market cap of $4.50 billion, a price-to-earnings ratio of 1,971.25 and a beta of 0.91. Krystal Biotech has a one year low of $86.03 and a one year high of $189.97.

Insider Activity

In other news, CAO Kathryn Romano sold 5,000 shares of the company’s stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the sale, the chief accounting officer now directly owns 12,936 shares in the company, valued at $2,145,823.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $170.96, for a total transaction of $4,274,000.00. Following the transaction, the insider now directly owns 1,550,882 shares in the company, valued at $265,138,786.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Kathryn Romano sold 5,000 shares of the stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $165.88, for a total value of $829,400.00. Following the transaction, the chief accounting officer now owns 12,936 shares in the company, valued at $2,145,823.68. The disclosure for this sale can be found here. Insiders have sold 38,087 shares of company stock worth $6,210,591 over the last three months. 14.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Several large investors have recently added to or reduced their stakes in KRYS. Commonwealth Equity Services LLC increased its stake in Krystal Biotech by 2.5% during the third quarter. Commonwealth Equity Services LLC now owns 4,426 shares of the company’s stock worth $513,000 after acquiring an additional 110 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Krystal Biotech by 1.7% during the third quarter. Bank of New York Mellon Corp now owns 98,220 shares of the company’s stock worth $11,394,000 after acquiring an additional 1,604 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Krystal Biotech by 11.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,487 shares of the company’s stock worth $520,000 after acquiring an additional 452 shares during the last quarter. Strs Ohio increased its stake in Krystal Biotech by 120.7% during the third quarter. Strs Ohio now owns 6,400 shares of the company’s stock worth $742,000 after acquiring an additional 3,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Krystal Biotech by 4.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,515 shares of the company’s stock worth $1,452,000 after acquiring an additional 566 shares during the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).